Endocrine Abstracts

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

Targeted therapy based on tyrosine kinase inhibitors (TKIs) constitutes a new treatment modality in thyroid cancer (TC). Their efficacy in prolongation of progression free survival in comparison to placebo has been documented in phase III studies. However, a problem of their tolerability has recently risen as numerous side effects influencing the quality of life may potentially limit their clinical use. Therefore, we decided to carry out a retrospective analysis of the frequen...

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...